Co-expression of High-mobility group box 1 protein (HMGB1) and receptor for advanced glycation end products (RAGE) in the prognosis of esophageal squamous cell carcinoma

Abstract

Esophageal cancer is a malignant type of cancer with a high mortality rate. The aim of this study is to determine co-expression patterns of High-mobility group box 1 protein (HMGB1) and receptor for advanced glycation end products (RAGE) in ESCC (esophageal squamous cell carcinoma) conditions and their prognostic role in cancer progression. The expression of HMGB1 and RAGE in ESCC tissues has been analyzed using qRT–PCR and Western blotting. Co-localized expression patterns of HMGB1 and RAGE in ESCC tissues were determined using immunohistochemistry and analyzed for clinical-pathological parameters. Overall survival was performed based on co-expression of HMGB1 and RAGE proteins. A higher expression pattern of HMGB1, and RAGE was observed at mRNA and protein level in the ESCC group compared to the adjacent tissue group. Expression of HMGB1 was significantly correlated with lymph node, metastasis, lymphatic invasion, and venous invasion (p < 0.05). RAGE expression exhibited a significant correlation with venous invasion. Overall survival was significantly shorter (P < 0.05) in the patients with co-expression of HMGB1 and RAGE compared to the patients without co-expression. A significant difference in the overall survival was evident between the patients with co-expression of HMGB1 and RAGE and the patients without coexpression. HMGB1 and RAGE expression patterns were associated with aggressive metastatic characteristics of ESCC. The co-expression of HMGB1 and RAGE was correlated with shorter survival times. Results concluded the co-expression patterns of HMGB1 and RAGE exhibited a prognostic relevance in ESCC conditions.

Association of Definitive Radiotherapy for Esophageal Cancer and the Incidence of Secondary Head and Neck Cancers: A SEER Population-Based Study

“…The long-term risks associated with RT should be studied closely as the improvements in cancer increase survival among cancer patients with RT [ 3 , 8 , 9 - 14 ]. During RT, the DNA of tumor cells is damaged by irradiation [ 15 , 16 ].…”

Serine and one-carbon metabolism sustain non-melanoma skin cancer progression

“…Unlike cSCCs, one of the main factors affecting the low survival rate of HNSCC, is the high percentage of diagnosis at advanced stage, being the recurrence rate of about 50% during the first 2 years from diagnosis. For this reason, several clinical and/or pathological parameters have been indicated to predict prognosis, recurrence, and survival, and to drive the therapeutic choice [31][32][33][34][35][36][37]. Notably, cSCCs and HNSCCs display hallmarks of solid tumors mildly responsive to systemic immunotherapy [38][39][40][41][42][43][44][45].…”